Previous 10 | Next 10 |
ARCA biopharma (NASDAQ: ABIO ) +59% on launching AB201 program in COVID-19. More news on: ARCA biopharma, Inc., PhaseBio Pharmaceuticals, Inc., Technical Communications Corporation, Stocks on the move, , Read more ...
PhaseBio Pharmaceuticals (NASDAQ: PHAS ) +81% after-hours as the Food & Drug Administration authorized the company to proceed with VANGARD, "a potentially pivotal clinical trial to evaluate PB1046 as a treatment for hospitalized COVID-19 patients who are at high risk for rapid c...
PhaseBio receives clearance of IND application from U.S. FDA under Coronavirus Treatment Acceleration Program (CTAP) “VANGARD” trial will assess the efficacy and safety of PB1046 in hospitalized COVID-19 patients at high risk for rapid clinical deterioration and acute res...
PhaseBio Pharmaceuticals (NASDAQ: PHAS ): Q1 GAAP EPS of -$0.52 misses by $0.11 . More news on: PhaseBio Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Initiated PB2452 Phase 3 Trial for the Reversal of the Antiplatelet Effects of Ticagrelor PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today ...
PhaseBio Pharmaceuticals (NASDAQ: PHAS ): Q4 GAAP EPS of -$0.39 beats by $0.01 . More news on: PhaseBio Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
Recently Initiated PB2452 Phase 3 Trial for the Reversal of the Antiplatelet Effects of Ticagrelor Received FDA Breakthrough Therapy Designation and EMA PRIME Designation for PB2452 Secured PB2452 Financing and Co-Development Collaboration with SFJ Pharmaceuticals® MALVER...
The following slide deck was published by PhaseBio Pharmaceuticals, Inc. in conjunction with this Read more ...
MALVERN, Pa. and SAN DIEGO, Feb. 26, 2020 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced that Chief Executive...
MALVERN, Pa. and SAN DIEGO, Feb. 13, 2020 (GLOBE NEWSWIRE) -- PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiopulmonary diseases, today announced the appointment of A...
News, Short Squeeze, Breakout and More Instantly...
PhaseBio Pharmaceuticals Inc. Company Name:
PHAS Stock Symbol:
NASDAQ Market:
Bidding Process and Auction Projected to Conclude December 2022 PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today announced that...
PhaseBio Pharmaceuticals, Inc. (Nasdaq: PHAS), a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for cardiovascular diseases, today reported financial results for the second quarter ended June 30, 2022, and provided an upd...